Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Oct;14(5):1124-36.
doi: 10.1007/s10461-009-9635-x.

Adherence and its measurement in phase 2/3 microbicide trials

Elizabeth E Tolley  1 , Polly F Harrison, Els Goetghebeur, Kathleen Morrow, Robert Pool, Doug Taylor, Stephanie N Tillman, Ariane van der Straten
Affiliations
Review

Adherence and its measurement in phase 2/3 microbicide trials

Elizabeth E Tolley et al. AIDS Behav. 2010 Oct.

Abstract

Adherence optimization and measurement have emerged as critically challenging issues for clinical trials of topical microbicides. Although microbicide trials have routinely collected adherence data, their utilization in trial design, implementation, and interpretation has been inconsistent. Drawing on data-driven presentations from several focused meetings, this paper synthesizes lessons from past microbicide trials and provides recommendations for future trials of microbicide and other HIV prevention technologies. First, it describes four purposes for adherence data collection, with particular attention to intention-to-treat versus adherence-adjusted analyses for determining effectiveness. Second, the microbicide field's experiences with adherence measures and data collection modes are discussed, including the strengths and weaknesses of various options and approaches for improving measurement. Then, several approaches to optimizing trial participants' adherence are presented. The paper concludes with a set of recommendations for immediate use or further research.

PubMed Disclaimer

References

    1. FHI. Phase 3 Trial in Nigeria Evaluating the Effectiveness of SAVVY Gel in Preventing HIV Infection in Women Will Close. 2006. http://www.fhi.org/en/aboutfhi/media/releases/phase3savvy082806.htm. Accessed 11 November 2009.
    1. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977–87. - PubMed
    1. Stover K. Anti-HIV gel shows promise in large-scale study in women. NIH news (serial on the Internet). 2009. http://www3.niaid.nih.gov/news/newsreleases/2009/HPTN_035_gel.htm. Accessed 9 Feb 2009.
    1. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360:971–977. doi: 10.1016/S0140-6736(02)11079-8. - DOI - PubMed
    1. Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463–472. doi: 10.1056/NEJMoa0707957. - DOI - PubMed

MeSH terms

Substances